{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-24-000360","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.866685+00:00","generated_at":"2026-06-04T01:41:58.461234+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation","bullets":["Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.","At pre-specified week 2 endpoint, effect size=0.79, suggesting early onset of action.","Interim results compare favorably to Brexpiprazole's Phase 3 (Cohen's d 0.35, LS mean -5.32).","Trial ongoing (n=26 interim); final results may differ as enrollment continues in US and Canada.","IGC-AD1 targets CB1 receptor, neuroinflammation, and inflammasome-3 pathways."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-24-000360","json":"https://secwatch.observer/filing/0001185185-24-000360.json","markdown":"https://secwatch.observer/filing/0001185185-24-000360.md","text":"https://secwatch.observer/filing/0001185185-24-000360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000360/0001185185-24-000360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000360/igcpharma20240320_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:41:58.461234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}